Legend Biotech’s Carvykti, a cell therapy for relapsed or lenalidomide-refractory multiple myeloma, demonstrated significant improvement in overall survival compared to standard therapies in a three-year follow-up study. The data presented at the International Myeloma Society Annual Meeting suggests that Carvykti could become a leading treatment option for patients after their first relapse.
2seventy bio, Inc. (TSVT) and its partner Bristol Myers Squibb (BMY) announced the discontinuation of enrollment in the KarMMa-9 Phase 3 study for Abecma in newly diagnosed multiple myeloma. This decision is driven by a focus on capital allocation and accelerating the path to profitability. Despite the discontinuation, Abecma continues to see positive momentum in earlier lines of treatment, with expected U.S. revenue growth of 30% in the third quarter.
The FDA has approved Sanofi’s Sarclisa (siltuximab) in combination with VRd as a first-line treatment for adult patients with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. This approval makes Sarclisa the first anti-CD38 therapy in combination with VRd to significantly reduce disease progression or death in this patient population.
